NanoViricides Inks Agreement for Orphan Drug Strategy with Only Orphans Cote

NanoViricides, Inc., a leading company in developing broad-spectrum antivirals, has signed a Master Services Agreement with Only Orphans Cote, LLC, to advance its orphan drug strategy for NV-387. This drug has shown promising results against orthopoxvirus and Measles in animal studies, which positions it for orphan drug designation by the US FDA.

Orphan drug designation offers benefits such as tax credits, exemption from user fees, and possible market exclusivity. NV-387 could be a valuable asset in pandemic preparedness due to its broad-spectrum antiviral properties. With measles cases on the rise and the potential threat of Smallpox as a bioterrorism agent, NV-387's development is timely.

The expertise of Dr. Timothy Cote, former Director of the US FDA Office of Orphan Products Development, enhances NanoViricides’ regulatory approach. As viruses mutate minimally for NV-387 to remain effective, it offers a promising solution to global viral threats.